Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
NCT00396279 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37
Last updated 2022-11-08
Summary
To determine how safe and effective denosumab is in treating patients with giant cell tumor of bone.
Conditions
- GCT
- Giant Cell Tumor of Bone
Interventions
- BIOLOGICAL
-
Administered by subcutaneous injection
- DIETARY_SUPPLEMENT
-
Calcium/Vitamin D
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-07-10
- Primary Completion
- 2008-04-07
- Completion
- 2011-02-01
More Related Trials
-
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
NCT00459069 ·Status: COMPLETED ·Phase: PHASE1
-
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
NCT00050323 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract
NCT02632019 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
NCT00458536 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer
NCT03410732 ·Status: UNKNOWN ·Phase: PHASE2
-
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
NCT03638765 ·Status: UNKNOWN ·Phase: PHASE1
-
GI Complications in Cancer Immunotherapy Patients
NCT02784366 ·Status: UNKNOWN
-
DENdritic Cell Immunotherapy for Mesothelioma
NCT03610360 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Engineered Dendritic Cell Vaccines for Multiple Myeloma
NCT06435910 ·Status: RECRUITING ·Phase: PHASE1
-
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
NCT04550663 ·Status: UNKNOWN ·Phase: PHASE1
-
Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors
NCT00576537 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
NCT04166006 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer
NCT01637805 ·Status: UNKNOWN ·Phase: PHASE1
-
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT01171469 ·Status: COMPLETED ·Phase: PHASE1
-
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
NCT01042366 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of γδ T Cell Against Gastric Cancer
NCT02585908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
NCT01973322 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348 ·Status: UNKNOWN ·Phase: PHASE2
-
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT00576641 ·Status: COMPLETED ·Phase: PHASE1
-
External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
NCT00365872 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
NCT00458653 ·Status: COMPLETED ·Phase: PHASE1
-
Dendritic Cell Based Therapy of Metastatic Breast Cancer
NCT00197925 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
NCT03434912 ·Status: UNKNOWN
-
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
NCT06626269 ·Status: RECRUITING ·Phase: NA
-
Neoantigen-expanded Autologous Immune Cell Therapy
NCT05020119 ·Status: UNKNOWN ·Phase: PHASE1